Takeuchi, Hiroyoshi

写真a

Affiliation

School of Medicine, Department of Neuropsychiatry (Shinanomachi)

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)

 

Research Areas 【 Display / hide

  • Psychiatric science

Research Keywords 【 Display / hide

  • Antipsychotics

  • Schizophrenia

 

Papers 【 Display / hide

  • Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports

    Kirino S., Sakuma M., Misawa F., Fujii Y., Uchida H., Mimura M., Takeuchi H.

    Progress in Neuro-Psychopharmacology and Biological Psychiatry (Progress in Neuro-Psychopharmacology and Biological Psychiatry)  96 2020.01

    ISSN  02785846

     View Summary

    © 2019 Elsevier Inc. Objective: This systematic review aimed to elucidate the relationship between polydipsia and antipsychotics. Methods: We systematically searched MEDLINE, Embase, and PsycINFO, and included clinical studies and case reports on polydipsia induced or improved by antipsychotics. Results: We identified 61 articles: 1 double-blind randomized controlled trial (RCT), 4 single-arm trials, 1 cross-sectional study, 3 case series, and 52 case reports. The double-blind RCT demonstrated no significant difference in improvement in polydipsia between olanzapine and haloperidol. Two single-arm trials showed that polydipsia improved during clozapine treatment, whereas the other 2 showed that risperidone did not improve polydipsia. The cross-sectional study showed the prevalence of hyponatremia with first-generation antipsychotics (FGAs: 26.1%) and second-generation antipsychotics (SGAs: 4.9%). Two case series reported that clozapine improved polydipsia; the other one indicated that patients with polydipsia who were treated with FGAs had schizophrenia (70.4%) and mental retardation (25.9%). Of 90 cases in the case reports, 67 (75.3%) were diagnosed with schizophrenia. Of 83 cases in which antipsychotic treatment started before the onset of polydipsia, 75 (90.3%) received FGAs, particularly haloperidol (n = 24, 28.9%), and 11 (13.3%) received risperidone. Among 40 cases in which polydipsia was improved following antipsychotic treatment, 36 (90.0%) received SGAs, primarily clozapine (n = 14, 35.0%). Conclusions: Although the causal relationship between polydipsia and antipsychotics remains unclear because of the paucity of high-quality studies, antipsychotics with high affinity to dopamine D2 receptors may be associated with an increased risk of polydipsia while clozapine may be effective for treating polydipsia.

  • Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology

    Koizumi T., Suzuki T., Pillai N., Bies R., Takeuchi H., Yoshimura K., Mimura M., Uchida H.

    Journal of Psychiatric Research (Journal of Psychiatric Research)  117   1 - 6 2019.10

    ISSN  00223956

     View Summary

    © 2019 Elsevier Ltd The objective of this study was to investigate possible circadian pattern of psychotic symptoms in patients with schizophrenia, which could be reflected on the dosing schedule/regimen, i.e. chrono-pharmacology. Patients with schizophrenia (ICD-10) who reported having auditory hallucination, receiving monotherapy with risperidone, olanzapine or paliperidone for at least two weeks were included. The subjects were provided a diary and asked to record the time and duration of auditory hallucinations during the eight time periods (i.e. 00:00–03:00, 03:00–06:00, 06:00–09:00, 09:00–12:00, 12:00–15:00, 15:00–18:00, 18:00–21:00, and 21:00–24:00). In the diary, times of medication doses and sleep were also recorded. Time and degree of peak and trough dopamine D2 receptor blockade with antipsychotics were estimated from 2 sparsely collected plasma drug concentrations. The prevalence and duration of auditory hallucinations were statistically examined among the eight time periods, respectively. Forty-nine patients participated in this study (mean ± SD age, 50.7 ± 14.8 years; 36 men (73.5%); 34 inpatients (69.4%)). Auditory hallucinations occurred most frequently and lasted for the longest duration in the period of 18:00–21:00 (75.5% (37/49) and 1.37 ± 1.67 h). This happened despite the fact that the difference in D2 receptor occupancy between the peak and trough was less than 2%, indicating a stable drug delivery. Since the dopamine D2 receptor blockade by antipsychotics was stable, the nocturnal circadian pattern found in this study may reflect intrinsic dopaminergic fluctuation or generally quieter environments at night. These circadian patterns may be considered to devise individualized treatment approach in the context of “chrono-pharmacology” for patients with schizophrenia.

  • Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis

    Matsui K., Tokumasu T., Takekita Y., Inada K., Kanazawa T., Kishimoto T., Takasu S., Tani H., Tarutani S., Hashimoto N., Yamada H., Yamanouchi Y., Takeuchi H.

    Schizophrenia Research (Schizophrenia Research)  209   50 - 57 2019.07

    ISSN  09209964

     View Summary

    © 2019 Elsevier B.V. Background: While recent meta-analyses have reported the superiority of antipsychotic polypharmacy (APP) over antipsychotic monotherapy (APM) in schizophrenia, switching to APM can be beneficial in terms of side effects. To determine whether patients receiving APP should switch to APM or stay on APP, we conducted a systematic review and meta-analysis. Methods: Randomized controlled trials (RCTs) examining a switch from APP to APM vs. staying on APP were systematically selected from a previous meta-analysis comparing APP with APM in patients with schizophrenia. In addition, we conducted an updated systematic literature search using MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Data on study discontinuation, relapse, psychopathology, neurocognition, extrapyramidal symptoms, and body weight/body mass index (BMI) were extracted and synthesized. Results: A total of 6 RCTs involving 341 patients were included. All studies examined a switch from 2 antipsychotic agents to a single agent. Clozapine-treated patients were included in 3 studies. There was a significant difference in study discontinuation due to all causes in favor of staying on APP (N = 6, n = 341, RR = 2.28, 95% CI = 1.50–3.46, P < 0.001). There were no significant differences in relapse, any psychopathology, neurocognition, extrapyramidal symptoms, or body weight/BMI between the 2 groups. The quality of evidence was low to very low. Conclusions: The findings suggest that clinicians should closely monitor patient condition when switching to APM after receiving 2 antipsychotics. Given the low to very low overall quality of the evidence, the findings should be considered preliminary and inconclusive.

  • Pharmacological interventions for prevention of weight gain in people with schizophrenia

    Agarwal S., Ahsan Z., Lockwood J., Duncan M., Takeuchi H., Cohn T., Taylor V., Remington G., Faulkner G., Hahn M.

    Cochrane Database of Systematic Reviews (Cochrane Database of Systematic Reviews)  2019 ( 6 )  2019.06

     View Summary

    © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effects of pharmacological interventions for preventing weight gain in people with schizophrenia.

  • Pharmacological interventions for reduction of weight gain in people with schizophrenia

    Hahn M., Agarwal S., Ahsan Z., Lockwood J., Duncan M., Takeuchi H., Cohn T., Taylor V., Remington G., Faulkner G.

    Cochrane Database of Systematic Reviews (Cochrane Database of Systematic Reviews)  2019 ( 6 )  2019.06

     View Summary

    © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effects of pharmacological interventions for treating weight gain in people with schizophrenia.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

Presentations 【 Display / hide

  • Antipsychotic treatment algorithm for first episode schizophrenia - a guide for clinicians

    Agid, Ofer, Fervaha, Gagan, Zipursky, Robert, Takeuchi, Hiroyoshi, Gorge, Foussias, Shireen, Huma, Remington, Gary

    EARLY INTERVENTION IN PSYCHIATRY, 2016.10

  • Depressive Symptoms and Progressive Hippocampal Volume Atrophy Accelerates the Conversion Process to Dementia from Mild Cognitive Impairment

    Chung, Jun Ku, Caravaggio, Fernando, Chakravarty, Mallar, Gerretsen, Philip, Graff-Guerrero, Ariel, Iwata, Yusuke, Mulsant, Benoit, Nakajima, Shinichiro, Patel, Raihaan, Plitman, Eric, Takeuchi, Hiroyoshi

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016.06

  • Synergic Effect of Depressive Symptoms and Small Hippocampal Volume Accelerates the Conversion Process to Dementia from Mild Cognitive Impairment

    Chung, Jun Ku, Plitman, Eric, Nakajima, Shinichiro, Chakravarty, Mallar, Caravaggio, Fernando, Takeuchi, Hiroyoshi, Gerretsen, Philip, Iwata, Yusuke, Patel, Raihaan, Mulsant, Benoit, Graff-Guerrero, Ariel

    BIOLOGICAL PSYCHIATRY, 2016.05

  • Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data (vol 150, pg 373, 2013)

    Takeuchi, Hiroyoshi, Suzuki, Takefumi, Bies, Robert R., Remington, Gary, Mamo, David C., Pollock, Bruce G., MasaruMimura, Uchida, Hiroyuki

    SCHIZOPHRENIA RESEARCH, 2015.03

  • 非定型抗精神病薬の普及度と適応に関する研究

    Tomita Masayuki, Watanabe Kouichirou, Kikuchi Toshiaki, Takeuchi Hiroyoshi, Kishimoto Taishirou, Nomura Kensuke, Nakagawa Atsuo, Yamazawa Ryouko, Uchida Hiroyuki, Suzuki Takefumi, Nozaki Shouko, Tomita Atsuko, Takano Harumasa, Inagaki Ataru, Yagi Gouhei

    第12回日本臨床精神神経薬理学会, 2002.10, Poster (general)

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 投与回数とゲノム薬理学による統合失調症の抗精神病薬アドヒアランス向上戦略

    2018.04
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 竹内 啓善, Grant-in-Aid for Early-Career Scientists , Principal Investigator

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, PSYCHIATRY

    2021

  • ISSUES IN PSYCHOPATHOLOGY

    2021

  • LECTURE SERIES, PSYCHIATRY

    2020

  • ISSUES IN PSYCHOPATHOLOGY

    2020